Biofrontera (BFRI) Other financing activities (2021 - 2022)
Biofrontera's (BFRI) quarterly Other financing activities came in at $4.8 million in Q4 2022, down 66.84% year-on-year from $14.4 million in Q4 2021, and up 200.0% quarter-over-quarter from -$4.8 million in Q3 2022.
Biofrontera (BFRI) Other financing activities (2021 - 2022) Analysis & Trends
Biofrontera's Other financing activities history runs 2 years deep, the most recent figure standing at $4.8 million for Q4 2022.
- On a quarterly basis, Other financing activities fell 66.84% year-over-year to $4.8 million in Q4 2022; TTM through Dec 2022 was $23.7 million, a N/A change from a year earlier, with the FY2022 full-year figure at $9.4 million, down 37.37% from the prior year.
- Other financing activities advanced to $4.8 million in Q4 2022 per BFRI's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Other financing activities topped out at $14.4 million in Q4 2021 and bottomed at -$4.8 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Biofrontera | 12.70 Mn | 6.29 Mn | 14.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 4.76 Mn |
| Dec 31, 2022 | 4.76 Mn |
| Sep 30, 2022 | -4.76 Mn |
| Sep 30, 2022 | -4.76 Mn |
| Jun 30, 2022 | 9.39 Mn |
| Jun 30, 2022 | 9.39 Mn |
| Dec 31, 2021 | 14.36 Mn |
| Dec 31, 2021 | 14.36 Mn |
| Sep 30, 2021 | 121,000.00 |
| Sep 30, 2021 | 121,000.00 |